CORSYM
LOE ApproachingNDAORALSUSPENSION, EXTENDED RELEASE
Approved
Jan 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORSYM is an oral extended-release suspension approved in 1984 by UCB Pharma as a small-molecule NDA. The specific indication, mechanism of action, and pharmacologic class are not publicly detailed in available data. Patient population and clinical use case remain unspecified.
LOE Approaching
Product is in late-stage lifecycle with modest competitive pressure (30/100), signaling a declining or maintenance-focused brand team with limited expansion opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect CORSYM's mature, non-growth status. Roles available are primarily defensive: managing legacy product compliance, pricing, and market maintenance rather than launching innovation or expanding market share. Career growth on this product is limited; professionals should expect transition planning.
Brand ManagerRegulatory Affairs Specialist
Worked on CORSYM at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.